Stage IIIB Breast Cancer Terminated Phase 2 Trials for Everolimus (DB01590)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02273752Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTreatment